Open Access

CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?

  • Keri N Althoff1Email author,
  • Kelly A Gebo2,
  • Stephen J Gange1,
  • Marina B Klein3,
  • John T Brooks4,
  • Robert S Hogg5,
  • Ronald J Bosch6,
  • Michael A Horberg7,
  • Michael S Saag8,
  • Mari M Kitahata9,
  • Joseph J Eron10,
  • Sonia Napravnik10,
  • Sean B Rourke11,
  • M John Gill12,
  • Benigno Rodriguez13,
  • Timothy R Sterling14,
  • Steven G Deeks15,
  • Jeffrey N Martin16,
  • Lisa P Jacobson1,
  • Gregory D Kirk1,
  • Ann C Collier9,
  • Constance A Benson17,
  • Michael J Silverberg7,
  • James J Goedert18,
  • Rosemary G McKaig19,
  • Jennifer Thorne20,
  • Anita Rachlis21,
  • Richard D Moore2,
  • Amy C Justice22 and
  • for the North American AIDS Cohort Collaboration on Research and Design
AIDS Research and Therapy20107:45

https://doi.org/10.1186/1742-6405-7-45

Received: 21 September 2010

Accepted: 15 December 2010

Published: 15 December 2010

Abstract

We assessed CD4 count at initial presentation for HIV care among ≥50-year-olds from 1997-2007 in 13 US and Canadian clinical cohorts and compared to <50-year-olds. 44,491 HIV-infected individuals in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) were included in our study. Trends in mean CD4 count (measured as cells/mm3) and 95% confidence intervals ([,]) were determined using linear regression stratified by age category and adjusted for gender, race/ethnicity, HIV transmission risk and cohort. From 1997-2007, the proportion of individuals presenting for HIV care who were ≥50-years-old increased from 17% to 27% (p-value < 0.01). The median CD4 count among ≥50 year-olds was consistently lower than younger adults. The interaction of age group and calendar year was significant (p-value <0.01) with both age groups experiencing modest annual improvements over time (< 50-year-olds: 5[4 , 6] cells/mm3; ≥50-year-olds: 7[5 , 9] cells/mm3), after adjusting for sex, race/ethnicity, HIV transmission risk group and cohort; however, increases in the two groups were similar after 2000. A greater proportion of older individuals had an AIDS-defining diagnosis at, or within three months prior to, first presentation for HIV care compared to younger individuals (13% vs. 10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed.

Findings

We recently reported that the median CD4 count at first presentation for HIV care in the US and Canada increased from 256 (IQR: 96-455) to 317 (IQR: 135-517) from 1997 to 2007, yet remained below 350 cells/mm3 - the current cut-off for initiating highly active antiretroviral therapy (HAART) [1, 2]. Over the study period, there was an increase in the median age at first presentation for HIV care (from 40 to 43 years in 1997 to 2007, p < 0.01) [1]. According to the Centers for Disease Control and Prevention (CDC) 10% of the total incident HIV infections occurring in the US in 2006 were among adults ≥50-years-old [3]. Further, the prevalence of HIV infection in individuals ≥50 years of age is rapidly increasing [4, 5], yet there is evidence that this older age group may not be as aware of HIV infection and the need for preventive measures and less likely to be tested and seek care early [69]. As this is the largest cohort collaboration of HIV-infected individuals in North America, we have conducted a new analysis that focuses on CD4 at first presentation for HIV care among patients ≥50-years-old.

We briefly describe study population and analytical methods; more details are provided in Althoff et al. [1].

All patients were enrollees in clinical care cohorts contributing to the North American Cohort Collaboration on Research and Design (NA-ACCORD) [10], a regional group of the International Epidemiological Databases to Evaluate AIDS (IeDEA) project. Each cohort's participation in NA-ACCORD was approved by the respective local institutional review boards. All 14 NA-ACCORD clinical cohorts agreed to participate in this study although one was excluded because their study population enrollment criteria restricted to those in later stages of HIV disease. These 13 clinical cohorts have clinical sites in 17 US states, Washington DC, and 3 Canadian provinces. Our primary focus was on HIV-infected adults who were ≥50 years of age and who first presented for clinical care between January 1997 and December 2007, as compared to individuals presenting at younger ages. First presentation for HIV clinical care was defined as the date (month and year) at which the first CD4 count was reported.

The first measured CD4 was our outcome of interest. The month and year in which the CD4 was measured were recorded. If there was more than one CD4 measurement in the first month at presentation for HIV care, we calculated the mean CD4 count for the month. Other information obtained at first presentation for care included self-reported year of birth, gender, race/ethnicity (as black, white, Latino and other/unknown) and HIV transmission risk group (male-to-male sex (MSM), injection drug use (IDU) including MSM/IDU, heterosexual contact and other/unknown).

Statistical comparisons of demographic and clinical characteristics across calendar dates were made using the Cochran-Armitage trend test for categorical variables or the Cuzick trend test for continuous variables. We determined the median absolute CD4 count and interquartile range (IQR) at first presentation for HIV clinical care annually from 1997 through 2007, by age group. Multivariate linear regression models were used to describe the annual trends in estimated mean CD4 count using a linear variable for year, stratified by age group and adjusting for cohort demographic and risk characteristics; 95% confidence intervals ([,]) were also estimated using these models. Sensitivity analyses were conducted by omitting participants from the Veterans Aging Cohort Study (VACS) and the HIV Research Network (HIVRN) as these two cohorts contribute ≈50% of the participants in the NA-ACCORD and the median age in the VACS was slightly older. Results with a two-sided p-value of <0.05 were considered statistically significant. Analyses were conducted using SAS, version 9.

After excluded individuals contributing data during the first year that the cohort contributed data to the NA-ACCORD to remove individuals who may have been previously in care, a total of 67,961 adults received HIV clinical care at one of the participating NA-ACCORD sites between 1997 and 2007 and had complete date and CD4 measurement information. Of these, 21,983 (32%) had a prior history of antiretroviral therapy or HIV-1 RNA results and 1,487 (2%) had an AIDS-defining diagnosis recorded more than 3 months prior to the first recorded CD4 count. These individuals were excluded as they were likely to have been previously in care. Our study population consisted of 44,491 HIV-infected individuals.

The proportions of individuals who were < and ≥50-years-old who first presented for HIV care each year are shown in Table 1; additional characteristics of the study population can be found in Althoff et al. [1]. From 1997-2007, the proportion of individuals presenting for HIV care who were aged ≥50 years increased from 17% to 27% (p-value < 0.01). The increase over time in median CD4 count at first presentation for care was similar in absolute magnitude in both age groups (67 cells/mm3 and 63 cells/mm3 from 1997 to 2007 among <50-year-olds and ≥50-year-olds, respectively). However, the ≥50-year-olds had a median CD4 count of 266 cells/mm3, compared to 336 cells/mm3 among <50-year-olds, in 2007.
Table 1

Characteristics of N = 44,491 participating patients, by year at first presentation

 

Total

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

p-value

 

N = 44,491

N = 4,479

N = 4,412

N = 4,857

N = 5,262

N = 4,258

N = 4,063

N = 3,688

N = 3,773

N = 3,486

N = 3,354

N = 2,859

 

Age (years)

                         

18-< 50

35,093

79%

3,698

83%

3,624

82%

3,953

81%

4,244

81%

3,344

79%

3,158

78%

2,855

77%

2,912

77%

2,709

78%

2,516

75%

2,080

73%

< 0.01

≥50

9,398

21%

781

17%

788

18%

904

19%

1,018

19%

914

21%

905

22%

833

23%

861

23%

777

22%

838

25%

779

27%

< 0.01

AIDS-defining illness

                       

18-< 50

3,390

10%

417

11%

385

11%

362

9%

370

9%

344

10%

331

10%

277

10%

270

9%

251

9%

208

8%

175

8%

< 0.01

≥50

1,242

13%

142

18%

127

16%

119

13%

121

12%

133

15%

119

13%

105

13%

105

12%

102

13%

95

11%

74

9%

< 0.01

CD4+ T-cell Count (cells/mm 3 )

                       

18-< 50

                         

Median

298

269

277

275

284

293

313

296

312

323

333

336

< 0.01

IQR

112-493

100-467

96-481

99-464

104-494

100-494

124-501

114-504

127-499

134-500

141-512

152-522

 

≥50

                         

Median

251

203

211

246

261

234

272

274

261

272

273

266

< 0.01

IQR

90-457

80-390

65-403

88-440

102-464

88-443

111-457

92-475

83-487

81-511

107-491

111-494

 

P-values calculated using Cochran-Armitage test for categorical variables or Cuzick's test for continuous variables.

The median CD4 count was consistently lower in the ≥50-year-olds compared to the <50-year-olds from 1997 to 2007 (Figure 1). The proportion of individuals at first presentation for HIV care who had a CD4 count ≥350 cells/mm3 was lower in the ≥50-year-olds compared to the <50-year-olds; this proportion increased over time for both age groups.
Figure 1

Median CD4 count, and the proportion of individuals who have a CD4 count ≥350 cells/mm 3 , at first presentation for HIV clinical care.

In the multivariate analyses, the estimated annual change in CD4 count from 1997 to 2007 was higher among ≥50-year-olds years (7 [5 , 9] cells/mm 3) compared to <50-year-olds (5 [4 , 6] cells/mm3) adjusting for sex, race and ethnicity, HIV transmission risk group and cohort. Findings were similar in sensitivity analyses. The interaction of age group and calendar year was statistically significant (p-value <0.01). After restriction to the years 2000-2007 in the ≥50-year-olds, the estimated annual change in CD4 count was 4 [1, 7] cells/mm3, similar to the change in the <50-year-olds from 1997-2007 (5 [4, 6]cells/mm3).

Overall, the proportion of individuals who had an AIDS-defining diagnosis recorded at, or 3 months prior to, the first CD4 measurement was highest among those aged ≥50 years (< 50-year-olds: 10%; ≥50-year-olds: 13%; p-value < 0.01); in sensitivity analyses, these proportions increased (< 50-year-olds: 12%; ≥50-year-olds: 18%; p-value < 0.01). The proportions who had an AIDS-defining diagnosis at first presentation for care decreased from 1997 to 2007 in both age groups (Table 1). Older individuals had a greater proportion with an AIDS-defining diagnosis in all years, however this disparity decreased over time (Table 1); in sensitivity analyses the decreases were of less magnitude (≥50-year-olds: 20% in 1997 to 15% in 2007, p-value < 0.01; <50-year-olds: 13% in 1997 to 12% in 2007, p-value < 0.01). Finally, among individuals who had an AIDS-defining diagnosis at first presentation for care, the proportion of older individuals who had ≥2 AIDS-defining diagnosis was similar to that of younger individuals (18% vs. 19%, p = 0.19).

Our study has three important findings: 1) the proportion of individuals at first presentation for care who are aged ≥50 years has increased over the past 11 years; 2) older individuals at first presentation of care consistently had a lower median CD4 count compared to younger individuals; and 3) a greater proportion of older individuals have an AIDS-defining diagnosis at, or within three months prior to, first presentation for HIV care compared to younger individuals.

The increase in the proportion of individuals who were ≥50 years at first presentation for care has implications for effective HIV management and survival for older infected individuals. Older individuals initiating HAART have a decreased immune response [1118] and mortality increases with lower CD4 counts at HAART initiation [19]. In addition, older individuals at first presentation for care may have existing co-morbid conditions that may complicate HIV treatment decisions. From a public health perspective, a delay in presentation for treatment increases the risk for ongoing transmission [2023]. These data suggest improved screening by health providers may help detect HIV infection earlier and at younger ages.

The estimated mean annual increase in CD4 count for individuals aged < and ≥50 years is small and likely of little clinical relevance as the within-patient variation in CD4 counts is ~25%. More importantly, the annual median CD4 count is still well below the CD4 recommended for initiation of HAART [24]. The proportion of individuals presenting with a CD4 ≥350 cell/smm3 increased in all age groups, however, the proportion was approximately 10% lower among ≥50-year-olds. This suggests the potential for greater HIV treatment initiation guideline adherence if effective testing and treatment interventions target older individuals.

Finally, our data suggest older individuals are entering into care with advanced HIV disease. The CDC recently reported an increase in the proportion of ≥50-year-olds in the US who had a first HIV diagnosis within a year before AIDS diagnosis compared to 30-< 50-year-olds [25]; the Public Health Agency of Canada has noted the increase among ≥50 year-olds [26, 27]. Data from New York City showed the proportion of new HIV diagnoses that are concurrent with an AIDS diagnoses increased with older age [28].

There are limitations to our study, including our lack of data regarding time since seroconversion. We chose to stratify the data using a cut-off of 50 years. Although there were more than enough individuals for additional stratification at younger ages, additional stratification at older ages was not possible.

While all age groups are experiencing modest improvements in CD4 count at presentation over time, older individuals have not "caught up." These data suggest that targeted renewed prevention and testing strategies are needed in all age groups, including those ≥50-years-old.

Declarations

Acknowledgements

We are grateful to all patients, physicians, investigators, and staff involved in the NA-ACCORD. This work was supported by grants from the National Institutes of Health: U01-AI069918, U01-AA013566, U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590, U01-AI68634, U01-AI68636, U01-HD32632, M01-RR00071, M01-RR00079, M01-RR00083, M01-RR00722, P30-AI27757, P30-AI27767, P30-AI50410, P30-AI54999, R01-DA04334, R01-DA12568, R01-MH54907, R24-AI067039, Z01-CP010176, AHQ290-01-0012, N02-CP55504, R01-DA11602, AI-69432, K01-AI071754, R01-AA16893, K24-00432, K23-AI-61-0320. This work was also supported by the Centers for Disease Control (CDC200-2006-18797), the Canadian Institutes for Health Research (CIHR: TGF-96118; HCP-97105; CBR-86906; CBR-94036; KRS-86251; 169621) and the Canadian Trials Network (project number 242).

NA-ACCORD Participating cohorts (representatives):

• AIDS Link to the IntraVenous Experience (Gregory D.Kirk)

• Adult AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (Constance A. Benson, Ronald J. Bosch, Ann C. Collier)

• HAART Observational Medical Evaluation and Research (Robert S. Hogg, Richard Harrigan, Julio Montaner)

• HIV Outpatient Study (John T. Brooks, Kate Buchacz)

• HIV Research Network (Kelly A. Gebo)

• Johns Hopkins HIV Clinical Cohort (Richard D. Moore)

• John T. Carey Special Immunology Unit Patient Care and Research Database, Case Western Reserve University (Benigno Rodriguez)

• Kaiser Permanente Northern California (Michael A. Horberg, Michael J. Silverberg)

• Longitudinal Study of Ocular complications of AIDS (Jennifer E. Thorne)

• Multicenter Hemophilia Cohort Study-II (James J. Goedert)

• Multicenter AIDS Cohort Study (Lisa P. Jacobson)

• Montreal Chest Institute Immunodeficiency Service Cohort (Marina B. Klein)

• Ontario HIV Treatment Network Cohort Study (Sean B. Rourke, Anita R. Rachlis)

• Southern Alberta Clinic Cohort (M. John Gill)

• Studies of the Consequences of the Protease Inhibitor Era (Steven G, Deeks, Jeffery N. Martin)

• University of Alabama at Birmingham 1917 Clinic Cohort (Michael S. Saag, Michael Mugavero, James Willig)

• University of North Carolina, Chapel Hill HIV Clinic Cohort (Joseph J. Eron, Sonia Napravnik)

• University of Washington HIV Cohort (Mari M. Kitahata and Heidi M. Crane)

• Veterans Aging Cohort Study (Amy C. Justice, David Fiellin)

• Vanderbilt-Meharry CFAR Cohort (Timothy R. Sterling, Sam Stinette, Peter Rebeiro, David Haas)

• Women's Interagency HIV Study (Stephen J. Gange, Kathryn Anastos)

Executive Committee: Richard D. Moore, Michael S. Saag, Stephen J. Gange, Mari M. Kitahata, Rosemary G. McKaig, Aimee Freeman

Epidemiology/Biostatistics Core: Stephen J. Gange, Alison G. Abraham, Bryan Lau, Keri N. Althoff, Jinbing Zhang

Data Management Core: Mari M. Kitahata, Stephen E. Van Rompaey, Heidi M. Crane, Eric Webster, Liz Morton, Brenda Simon

Authors’ Affiliations

(1)
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health
(2)
Department of Medicine, Johns Hopkins University School of Medicine
(3)
Department of Medicine, McGill University
(4)
Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention
(5)
British Columbia Centre for Excellence and HIV/AIDS and Simon Fraser University
(6)
Department of Biostatistics, Harvard University
(7)
Division of Research, Kaiser Permanente Northern California
(8)
Department of Medicine, University of Alabama at Birmingham
(9)
Department of Medicine, University of Washington
(10)
Department of Medicine, University of North Carolina at Chapel Hill, Mason Farm Rd
(11)
Departments of Psychiatry and Neuroscience, University of Toronto
(12)
South Alberta HIV Clinic, University of Calgary, #3223
(13)
Department of Medicine, Case Western Reserve University
(14)
Department of Medicine, Vanderbilt University
(15)
Department of Medicine, University of California San Francisco
(16)
Department of Epidemiology and Biostatistics, University of California San Francisco
(17)
Department of Medicine, University of California San Diego
(18)
Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health
(19)
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health
(20)
Wilmer Eye Institute, Johns Hopkins University School of Medicine
(21)
Department of Medicine, University of Toronto
(22)
Department of Medicine, Yale University School of Medicine and the VA Connecticut Healthcare System

References

  1. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ: Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010, 50: 1512-1520. 10.1086/652650PubMed CentralView ArticlePubMedGoogle Scholar
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. 2008, 1-139.Google Scholar
  3. Centers for Disease Control and Prevention: Estimated percentage of new HIV infections by age - United States, 2006. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. 2009Google Scholar
  4. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report, 2006. Atlanta, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2008, 18:Google Scholar
  5. Luther VP, Wilkin AM: HIV infection in older adults. Clin Geriatr Med. 2007, 23: 567-83. vii 10.1016/j.cger.2007.02.004View ArticlePubMedGoogle Scholar
  6. Stall R, Catania J: AIDS risk behaviors among late middle-aged and elderly Americans. The National AIDS Behavioral Surveys. Arch Intern Med. 1994, 154: 57-63. 10.1001/archinte.154.1.57View ArticlePubMedGoogle Scholar
  7. el-Sadr W, Gettler J: Unrecognized human immunodeficiency virus infection in the elderly. Arch Intern Med. 1995, 155: 184-186. 10.1001/archinte.155.2.184View ArticlePubMedGoogle Scholar
  8. Abel T, Werner M: HIV risk behaviour of older persons. Eur J Public Health. 2003, 13: 350-352. 10.1093/eurpub/13.4.350View ArticlePubMedGoogle Scholar
  9. Winningham A, Corwin S, Moore C, Richter D, Sargent R, Gore-Felton C: The changing age of HIV: sexual risk among older African American women living in rural communities. Prev Med. 2004, 39: 809-814. 10.1016/j.ypmed.2004.03.005View ArticlePubMedGoogle Scholar
  10. Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT: Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol. 2007, 36: 294-301. 10.1093/ije/dyl286PubMed CentralView ArticlePubMedGoogle Scholar
  11. Manfredi R, Calza L, Cocchi D, Chiodo F: Antiretroviral treatment and advanced age: epidemiologic, laboratory, and clinical features in the elderly. J Acquir Immune Defic Syndr. 2003, 33: 112-114.View ArticlePubMedGoogle Scholar
  12. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G: Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001, 183: 1290-1294. 10.1086/319678View ArticlePubMedGoogle Scholar
  13. Knobel H, Guelar A, Valldecillo G, Carmona A, Gonzalez A, Lopez-Colomes JL: Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS. 2001, 15: 1591-1593. 10.1097/00002030-200108170-00025View ArticlePubMedGoogle Scholar
  14. Kalayjian RC, Landay A, Pollard RB, Taub DD, Gross BH, Francis IR: Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis. 2003, 187: 1924-1933. 10.1086/375372View ArticlePubMedGoogle Scholar
  15. Grabar S, Kousignian I, Sobel A, Le BP, Gasnault J, Enel P: Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS. 2004, 18: 2029-2038. 10.1097/00002030-200410210-00007View ArticlePubMedGoogle Scholar
  16. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP: Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007, 167: 684-691. 10.1001/archinte.167.7.684View ArticlePubMedGoogle Scholar
  17. Cuzin L, Delpierre C, Gerard S, Massip P, Marchou B: Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years. Clin Infect Dis. 2007, 45: 654-657. 10.1086/520652View ArticlePubMedGoogle Scholar
  18. Collaboration of Observational HIV Epidemiologic Research Europe (COHERE) Study Group: Response to combination antiretroviral therapy: variation by age. AIDS. 2008, 22: 1463-1473. 10.1097/QAD.0b013e3282f88d02View ArticleGoogle Scholar
  19. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC: Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009, 360: 1815-1826. 10.1056/NEJMoa0807252PubMed CentralView ArticlePubMedGoogle Scholar
  20. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK: Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999, 341: 394-402. 10.1056/NEJM199908053410602View ArticlePubMedGoogle Scholar
  21. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000, 342: 921-929. 10.1056/NEJM200003303421303View ArticlePubMedGoogle Scholar
  22. Modjarrad K, Chamot E, Vermund SH: Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS. 2008, 22: 2179-2185. 10.1097/QAD.0b013e328312c756PubMed CentralView ArticlePubMedGoogle Scholar
  23. Marks G, Crepaz N, Senterfitt JW, Janssen RS: Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005, 39: 446-453. 10.1097/01.qai.0000151079.33935.79View ArticlePubMedGoogle Scholar
  24. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA: Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis. 1994, 169: 28-36.View ArticlePubMedGoogle Scholar
  25. Hall HI, Geduld J, Boulos D, Rhodes P, An Q, Mastro TD: Epidemiology of HIV in the United States and Canada: current status and ongoing challenges. J Acquir Immune Defic Syndr. 2009, 51 (Suppl 1): S13-S20.View ArticlePubMedGoogle Scholar
  26. Public Health Agency of Canada: HIV and AIDS in Canada: Surveillance Report to December 31, 2006. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control. 2007Google Scholar
  27. Public Health Agency of Canada: HIV/AIDS Epi Updates, November 2007. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, 1-140. 2007Google Scholar
  28. Torian L, Wiewel E: Risk factors for concurrent diagnosis fo HIV/AIDS in New York City, 2004: The role of age, transmission risk, and country of birth. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California. 2007Google Scholar

Copyright

© Althoff et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement